The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Table 2 Arm A (vaccine + IL-2): patient profiles, clinical, and immunological outcomes

Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Immune response
Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Proliferative assay		Elispot
								Pre-vaccine	Post-vaccine	Pre-vaccine	Post-vaccine
1A	56	Colon	IV	2	PD	0.5	5.5	ND
2A	57	Colon	IV	3	PD	3.9	16.8	NA		-	-
3A	62	Colon	IV	3	PD	5.8	21.5	-	-	-	-
4A	50	Pancreatic	IV	3	PD	3.6	6.2	-	-	-	-
5A	60	Lung	IV	1	PD	1	2.8	ND
6A	59	Colon	IV	3	PD	3.5	8.9	NA
7A	52	Colon	NED	11	Completed	129+	129+	-	+	-	+
8A	68	Lung	IV	3	PD	3.6	13.1	-	-	-	-
9A	56	Colon	NED	10	PPS	18.8	37.2	-	+	-	+
10A	63	Colon	IV	3	PD	3.3	19.9	-	-	-	-
11A	42	Pancreatic	NED	6	PD	7.5	24.1	-	-	-	-
12A	39	Colon	NED	3	PD	6.2	23	-	-	-	-
13A	67	Colon	IV	3	PD	3.5	4.8	-	+	+	+
14A	51	Colon	NED	3	PD	7.1	41.3	-	-	-	-
15A	60	Pancreatic	IV	3	PPS/Lost to follow-up	2.7+	5.3	NA		-	-
16A	61	Colon	IV	3	PD	3.6	17.3	-	+	-	-

^#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.